Tricyclic Antidepressants and Cancer Risk
Author Information
Author(s): Walker A J, Card T, Bates T E, Muir K
Primary Institution: University of Nottingham
Hypothesis
Tricyclic antidepressants may have a protective effect against glioma and colorectal cancer.
Conclusion
Tricyclic antidepressants may help reduce the risk of colorectal cancer and glioma.
Supporting Evidence
- Statistically significant reduction in tricyclic prescriptions in glioma and colorectal cancer patients compared to controls.
- The effects were dose-dependent and time-dependent.
- No significant association was found for lung, breast, and prostate cancers.
Takeaway
This study found that taking certain antidepressants might help prevent some types of cancer, like brain and colon cancer.
Methodology
A case-control study using the General Practice Research Database to examine the association between tricyclic antidepressant use and cancer incidence.
Potential Biases
Confounding by indication, particularly with SSRIs and depression.
Limitations
Potential for residual confounding due to missing data on smoking, obesity, and alcohol use.
Participant Demographics
Median age of participants was 68.2 years, with 50.7% females.
Statistical Information
P-Value
0.0005 for glioma, 0.001 for colorectal cancer
Confidence Interval
Glioma: 0.42–0.81, Colorectal: 0.75–0.94
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website